Anixa Biosciences (NASDAQ:ANIX) Raised to “Hold” at Wall Street Zen

Anixa Biosciences (NASDAQ:ANIX) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday.

Other equities analysts also recently issued reports about the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Anixa Biosciences in a report on Monday, December 29th. D. Boral Capital reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Anixa Biosciences in a research report on Wednesday, February 4th. Finally, Zacks Research cut shares of Anixa Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 18th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $9.00.

Anixa Biosciences Trading Down 1.4%

ANIX opened at $2.85 on Friday. Anixa Biosciences has a 1-year low of $2.33 and a 1-year high of $5.46. The company has a market cap of $95.13 million, a P/E ratio of -8.14 and a beta of 0.48. The company has a fifty day moving average price of $3.05 and a two-hundred day moving average price of $3.55.

Anixa Biosciences (NASDAQ:ANIX) last issued its earnings results on Monday, January 12th. The company reported ($0.09) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.09). On average, research analysts forecast that Anixa Biosciences will post -0.41 EPS for the current fiscal year.

Insider Transactions at Anixa Biosciences

In other Anixa Biosciences news, Director Arnold M. Baskies acquired 10,000 shares of the stock in a transaction dated Wednesday, January 28th. The stock was purchased at an average cost of $3.04 per share, for a total transaction of $30,400.00. Following the acquisition, the director owned 135,000 shares in the company, valued at $410,400. The trade was a 8.00% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. 26.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Anixa Biosciences

Institutional investors have recently added to or reduced their stakes in the company. NewEdge Advisors LLC bought a new position in Anixa Biosciences in the 2nd quarter worth $33,000. Cetera Investment Advisers bought a new stake in Anixa Biosciences in the 4th quarter worth about $35,000. Northwestern Mutual Wealth Management Co. raised its position in Anixa Biosciences by 2,000.0% in the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 10,500 shares of the company’s stock worth $35,000 after buying an additional 10,000 shares during the last quarter. Benjamin Edwards Inc. purchased a new position in shares of Anixa Biosciences during the second quarter valued at approximately $37,000. Finally, Millennium Management LLC purchased a new stake in Anixa Biosciences during the 4th quarter valued at $38,000. Hedge funds and other institutional investors own 29.13% of the company’s stock.

Anixa Biosciences Company Profile

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.